SG11202104431PA - HUMANIZED ANTI-SIRPα ANTIBODIES - Google Patents
HUMANIZED ANTI-SIRPα ANTIBODIESInfo
- Publication number
- SG11202104431PA SG11202104431PA SG11202104431PA SG11202104431PA SG11202104431PA SG 11202104431P A SG11202104431P A SG 11202104431PA SG 11202104431P A SG11202104431P A SG 11202104431PA SG 11202104431P A SG11202104431P A SG 11202104431PA SG 11202104431P A SG11202104431P A SG 11202104431PA
- Authority
- SG
- Singapore
- Prior art keywords
- humanized anti
- sirpα antibodies
- sirpα
- antibodies
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18206594 | 2018-11-15 | ||
| PCT/EP2019/081523 WO2020099653A1 (en) | 2018-11-15 | 2019-11-15 | HUMANIZED ANTI-SIRPα ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104431PA true SG11202104431PA (en) | 2021-05-28 |
Family
ID=64331834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104431PA SG11202104431PA (en) | 2018-11-15 | 2019-11-15 | HUMANIZED ANTI-SIRPα ANTIBODIES |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210388107A1 (en) |
| EP (1) | EP3880707A1 (en) |
| JP (1) | JP7451520B2 (en) |
| KR (1) | KR20210093270A (en) |
| CN (1) | CN113412279A (en) |
| AU (1) | AU2019378101A1 (en) |
| BR (1) | BR112021009275A2 (en) |
| CA (1) | CA3118966A1 (en) |
| CL (1) | CL2021001260A1 (en) |
| IL (1) | IL282756A (en) |
| MX (1) | MX2021005761A (en) |
| SG (1) | SG11202104431PA (en) |
| WO (1) | WO2020099653A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190009A1 (en) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | Antibodies against signal-regulatory protein alpha and methods of use |
| CN110325549B (en) | 2016-12-09 | 2024-03-08 | 艾利妥 | anti-SIRP alpha antibodies and methods of use thereof |
| US10851164B2 (en) * | 2017-04-13 | 2020-12-01 | Aduro Biotech Holdings, Europe B.V. | Anti-SIRPα antibodies |
| BR112020018927A2 (en) | 2018-03-21 | 2021-01-05 | ALX Oncology Inc. | ANTIBODIES AGAINST ALPHA SIGN REGULATORY PROTEIN AND METHODS OF USE |
| WO2019226973A1 (en) | 2018-05-25 | 2019-11-28 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
| CN114790241A (en) * | 2021-01-26 | 2022-07-26 | 北京免疫方舟医药科技有限公司 | anti-TIGIT antibody and application thereof |
| KR20240027677A (en) * | 2021-06-04 | 2024-03-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Anti-SIRP-alpha antibody |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| RS52305B (en) | 2007-07-16 | 2012-12-31 | Genentech Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2010095940A2 (en) | 2009-02-20 | 2010-08-26 | To-Bbb Holding B.V. | Glutathione-based drug delivery system |
| CN101880324B (en) * | 2010-05-25 | 2012-10-17 | 中国人民解放军第二军医大学 | Monoclonal antibody of anti-human SIRPalpha, cell strain, preparation method and application thereof |
| JP2014519338A (en) * | 2011-06-16 | 2014-08-14 | ノバルティス アーゲー | Soluble proteins used as therapeutic agents |
| WO2013056352A1 (en) | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| MX2015008534A (en) | 2012-12-26 | 2017-07-04 | Oncosynergy Inc | ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF. |
| CN103665165B (en) * | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | Bi-specific antibody of a kind of targeted human CD47-SIRP signal α path and its production and use |
| CA2939293C (en) | 2014-03-11 | 2023-10-03 | The Board Of Trustees Of The Leland Standford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| EP3643727A1 (en) * | 2014-08-15 | 2020-04-29 | Merck Patent GmbH | Sirp-alpha immunoglobulin fusion proteins |
| WO2017178653A2 (en) | 2016-04-14 | 2017-10-19 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| CA3031034A1 (en) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
| JOP20190009A1 (en) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | Antibodies against signal-regulatory protein alpha and methods of use |
| CN110325549B (en) * | 2016-12-09 | 2024-03-08 | 艾利妥 | anti-SIRP alpha antibodies and methods of use thereof |
| US10851164B2 (en) | 2017-04-13 | 2020-12-01 | Aduro Biotech Holdings, Europe B.V. | Anti-SIRPα antibodies |
| TWI710574B (en) | 2017-05-16 | 2020-11-21 | 荷蘭商拜恩迪斯公司 | ANTI-SIRPα ANTIBODIES |
-
2019
- 2019-11-15 SG SG11202104431PA patent/SG11202104431PA/en unknown
- 2019-11-15 US US17/292,182 patent/US20210388107A1/en active Pending
- 2019-11-15 WO PCT/EP2019/081523 patent/WO2020099653A1/en unknown
- 2019-11-15 BR BR112021009275A patent/BR112021009275A2/en unknown
- 2019-11-15 CA CA3118966A patent/CA3118966A1/en active Pending
- 2019-11-15 KR KR1020217016769A patent/KR20210093270A/en unknown
- 2019-11-15 AU AU2019378101A patent/AU2019378101A1/en active Pending
- 2019-11-15 CN CN201980088956.2A patent/CN113412279A/en active Pending
- 2019-11-15 EP EP19808550.8A patent/EP3880707A1/en active Pending
- 2019-11-15 MX MX2021005761A patent/MX2021005761A/en unknown
- 2019-11-15 JP JP2021526658A patent/JP7451520B2/en active Active
-
2021
- 2021-04-28 IL IL282756A patent/IL282756A/en unknown
- 2021-05-13 CL CL2021001260A patent/CL2021001260A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021009275A2 (en) | 2022-01-04 |
| AU2019378101A1 (en) | 2021-05-27 |
| MX2021005761A (en) | 2021-08-11 |
| CA3118966A1 (en) | 2020-05-22 |
| JP7451520B2 (en) | 2024-03-18 |
| EP3880707A1 (en) | 2021-09-22 |
| WO2020099653A1 (en) | 2020-05-22 |
| KR20210093270A (en) | 2021-07-27 |
| CL2021001260A1 (en) | 2021-12-24 |
| JP2022509065A (en) | 2022-01-20 |
| CN113412279A (en) | 2021-09-17 |
| US20210388107A1 (en) | 2021-12-16 |
| IL282756A (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280780A (en) | Anti-tigit antibodies | |
| IL279235A (en) | Dll3-cd3 bispecific antibodies | |
| IL283812B (en) | Humanized anti-human-pd-1 antibody | |
| IL279352A (en) | Il-11ra antibodies | |
| IL280013A (en) | Anti-il36r antibodies | |
| IL278010A (en) | Galectin-10 antibodies | |
| IL282668A (en) | Humanized antibodies against c-kit | |
| IL282756A (en) | Humanized anti-sirpα antibodies | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| IL277030A (en) | Antibodies | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| SG11202007735TA (en) | Anti-her2 antibodies | |
| GB201811368D0 (en) | Antibody | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| IL282355A (en) | Exosome-targeting bispecific antibodies | |
| IL279823A (en) | Humanized antibodies against psma | |
| GB201806084D0 (en) | Antibodies | |
| GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| GB201819952D0 (en) | Antibodies | |
| GB201817309D0 (en) | Antibodies | |
| GB201817311D0 (en) | Antibodies | |
| GB201817312D0 (en) | Antibodies | |
| GB201817313D0 (en) | Antibodies | |
| GB201806099D0 (en) | Galectin-10 Antibodies |